Item 2.02 Results of Operations and Financial Condition.

On January 10, 2023, Halozyme Therapeutics, Inc., a Delaware corporation ("Halozyme"), issued a press release (the "Press Release") which contained information related to Halozyme's expected financial results of a completed fiscal period. A copy of the Press Release is attached hereto as Exhibit 99.1.



On January 10, 2023, Halozyme presented at the annual JP Morgan Healthcare
Conference to provide a corporate update on certain strategic programs and to
provide financial guidance for 2023. The slides used by Halozyme in making the
presentation contained information related to Halozyme's expected financial
results for a completed fiscal period. A copy of the slides used by Halozyme is
attached hereto as Exhibit 99.2.

Exhibits 99.1 and 99.2 are furnished under Item 2.02 of this report and shall
not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended, (the "Exchange Act") or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by reference in
any filing under the Securities Act of 1933, as amended, or the Exchange Act,
regardless of any general incorporation language in such filing.

Item 7.01 Regulation FD Disclosure.

The copy of the slides used by Halozyme in making the JP Morgan Healthcare Conference presentation attached hereto as Exhibit 99.2 is incorporated herein by reference and is expected to be used in subsequent presentations to interested parties, including analysts and stockholders.



This information is being furnished pursuant to Item 7.01 of this Report and
shall not be deemed to be "filed" for the purposes of Section 18 of the
Securities and Exchange Act of 1934, as amended, or otherwise subject to the
liabilities of that section and will not be incorporated by reference into any
registration statement filed by Halozyme, under the Securities Act of 1933, as
amended, unless specifically identified as being incorporated therein by
reference. This Report will not be deemed an admission as to the materiality of
any information in this Report that is being disclosed pursuant to Regulation
FD.

Please refer to page 2 of the presentation attached hereto as Exhibit 99.2 for a
discussion of certain forward-looking statements included therein and the risks
and uncertainties related thereto.

Item 9.01 Financial Statements and Exhibits.



Exhibits

Exhibit No.       Description

  99.1            Press release dated January 10, 2023
  99.2            Halozyme Therapeutics, Inc. corporate update

presentation, dated January 10, 2023


                  Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit
104               101)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses